MedTrace Logo

Feasibility Study of Platelet Activation and Inflammatory Response of Platelets in Hematopoietic Stem Cell Allograft Patients Post-transplant: Spontaneously and After Stimulation by an CMV Antigen

NCT03009708 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2018-05-14

No results posted yet for this study

Summary

Traditionally known for their role in haemostasis, platelets have also an immune role.

Platelets play a key role in immune mediator secretion, and interact with innate and adaptive immune cells, contributing to the fight against pathogens, as viruses.

Cytomegalovirus (CMV) is responsible of allograft patients' serious infections, because of the induced immune depression. Platelets activation for patients is not determined during the post-graft period, and platelet induced inflammation following a CMV infection is not described.

Conditions

  • Allograft

Interventions

OTHER

Blood samples

Two blood tubes will be collected each week during 8 weeks maximum for the present study. Samples will start at day 30 post-graft and finish at day 90 post-graft maximum.

Sponsors & Collaborators

  • Groupe sur l'Immunité des Muqueuses et Agents Pathogènes, (GIMAP)

    collaborator UNKNOWN

  • Association Stéphanoise Pour la Recherche en Hématologie-Oncologie (ASPHRO)

    collaborator UNKNOWN

  • Institut de Cancérologie de la Loire

    lead OTHER

Principal Investigators

  • CORNILLON Jérôme, PhD · Institut de Cancérologie Lucien Neuwirth

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-21
Primary Completion
2017-09-12
Completion
2017-11-06

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03009708 on ClinicalTrials.gov